We find ourselves in an exciting time in Alzheimer’s Disease (AD) research. As a result of longitudinal studies revealing amyloid and tau dynamics, we now have disease-modifying treatments demonstrating cognitive benefit in early symptomatic individuals. There may be even more benefit if these therapies could be administered earlier, before cognitive impairment.
Medical imaging plays a pivotal role in understanding the disease during this presymptomatic period when cognitive changes are subtle and difficult to detect. It’s important to stay current on the latest research about how these biomarkers are changing: both in terms of when (stage of the disease) and where (affected areas in the brain) and how these findings could impact your clinical development programs.
In this webinar, Perceptive’s Dr. David Cash will present how novel imaging and trial designs are improving accessibility and precision in presymptomatic AD research, including:
– How changes in amyloid burden, tau deposition and atrophy can be detected during the presymptomatic phase of AD
– How ultra low-field MRI and rapid MRI techniques can increase accessibility to imaging both in clinical research and in clinical trials
– How new trial designs are needed to define relevant treatment effects in presymptomatic AD
Join us to learn how imaging biomarkers can detect Alzheimer’s decades before symptoms, supporting earlier intervention and innovative trial designs.
Date: Tuesday, 30th September 2025
Time: 16:00
Venue: Online